Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer

BACKGROUND: The rational choice of drugs for treating patients with advanced non-small-cell lung cancer (NSCLC) is significantly impacted by changes in modern drug policy, health insurance negotiation, and budget impact analyses. Here, we provide a basis for rational drug use decisions in clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yao, Huang, Kaiyu, Sun, Sijia, Deng, Yahong, Xie, Xuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898067/
https://www.ncbi.nlm.nih.gov/pubmed/35256866
http://dx.doi.org/10.2147/RMHP.S352827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898067/
https://www.ncbi.nlm.nih.gov/pubmed/35256866
http://dx.doi.org/10.2147/RMHP.S352827

Ejemplares similares